 SHELTON, CT ACCESSWIRE May 21, 2020 NanoViricides, Inc. NYSE American:NNVC the Company, a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 1,400,000 shares of its common stock at a price of 7.30 per share, for aggregate gross proceeds of approximately 10.22 million, in a registered direct offering. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc., are acting as co-placement agents for the offering. 